Latest Biotechnology, Pharmaceutical and Healthcare News from Cancer Networks

16:08 EST 21st February 2018 | BioPortfolio

Here are the most relevant search results for "Cancer Networks" found in our extensive news archives from over 250 global news sources.

More Information about Cancer Networks on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Cancer Networks for you to read. Along with our medical data and news we also list Cancer Networks Clinical Trials, which are updated daily. BioPortfolio also has a large database of Cancer Networks Companies for you to search.

Showing News Articles 1–25 of 296 from Cancer Networks

Wednesday 21st February 2018

Perceived Narrowing of Racial Disparity in Prostate Cancer Outcomes Due to Screening

The observed narrowing of racial disparities in prostate cancer outcome since the advent of PSA screening is not as large as previously believed.

Obesity Associated With Improved Outcomes in Some Metastatic Melanomas

A retrospective review found that obesity is associated with improved progression-free and overall survival in certain patients with metastatic melanoma.

Tuesday 20th February 2018

Single-Agent Ibrutinib Active at 5 Years in CLL, SLL

Single-agent ibrutinib resulted in sustained efficacy and durable responses in treatment-naive or relapsed/refractory CLL or SLL, 5-year results show.

Survival Benefit From mAb Combo in Select Metastatic CRC Patients

A preplanned analysis of ctDNA found that a subpopulation of mCRC patients with acquired anti-EGFR resistance were sensitive to treatment with Sym004.

Dual HER2 Blockade/Chemo Improves Outcomes in Older Breast Cancer Patients

The addition of metronomic chemotherapy to dual HER2 blockade improved outcomes in older and frail patients with HER2-positive metastatic breast cancer.

Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome

A Guide for the Practicing OncologistThird Edition CLICK HERE TO ACCESS THE WHITE PAPER

Cabozantinib Shows Strong Activity in RAI-Refractory Thyroid Cancer

Cabozantinib showed significant antitumor activity in the treatment of differentiated thyroid cancer that progressed following surgery and radioactive iodine therapy, according to a new phase II study.

Adding Nivolumab to Standard First-Line Therapy Feasible in Advanced Head and Neck Cancer

An early phase trial found that it is feasible to combine nivolumab immunotherapy with radiation therapy and chemotherapy in patients with newly diagnosed local-regionally advanced head and neck cancers.

Durvalumab Shows Promise in Advanced Head and Neck Cancer

A phase II trial found that the immune checkpoint inhibitor durvalumab has promising clinical activity and is well tolerated both as monotherapy and in combination with tremelimumab in patients with heavily pretreated recurrent or metastatic head and neck cancer, whose tumors are PD-L1 low or negative.

Monday 19th February 2018

Reduced RT Feasible in Chemo-Sensitive HPV-Associated Head and Neck Cancer

Patients with human papillomavirus–associated head and neck cancers who respond well to induction therapy can receive substantially lower doses of radiation and still achieve good safety and efficacy outcomes, according to a new phase II trial.

Friday 16th February 2018

Pazopanib Improves PFS in Extensive-Disease SCLC, But Adds Toxicity

Maintenance therapy with pazopanib significantly prolonged progression-free survival in patients with extensive-disease small-cell lung cancer, but with toxicity.

FDA Approves First Treatment for Nonmetastatic CRPC

The US Food and Drug Administration (FDA) has approved the oral agent apalutamide (Erleada) for the treatment of nonmetastatic castration-resistant prostate cancer. The oral androgen-receptor inhibitor is the first FDA-approved treatment for patients with nonmetastatic castration-resistant disease and the first to be approved based on the endpoint of metastasis-free survival.

Thursday 15th February 2018

Bone Markers Can Predict Bone-Specific Recurrence in Early Breast Cancer

Several markers of bone formation and resorption were found to be predictive of bone-specific recurrence in patients with early breast cancer.

Polyp Burden Drops With Sulindac/Erlotinib Combo in FAP

Patients with familial adenomatous polyposis have an increased risk for colorectal polyps and cancer; however, treatment with a combination of sulindac and erlotinib reduced their colorectal polyp burden by more than two thirds.

Quiz: What Newly Approved Drug Treats Bone Metastases in Multiple Myeloma?

Test your knowledge in our latest quiz.

Thursday 1st February 2018

Quiz: Are Antidepressants Linked With Increased Ovarian Cancer Risk?

Test your knowledge in our latest quiz.

Quiz: Molecular Risk Stratification in Acute Myeloid Leukemia

Test your knowledge in our latest quiz.

Monday 29th January 2018

Therapeutic Vaccine Combination May Help Patients with Myelodysplastic Syndrome

A new study demonstrates that it is possible to vaccinate patients with MDS against a decitabine-induced antigen and that the level of induced expression is sufficient to trigger cytotoxicity in patient-derived vaccine induced T-cells.

Friday 26th January 2018

New Genetic Sequence Data Map May Lead to New Immunotherapies

ImmunoMap, which can examine t-cell receptor repertoire relatedness, may help predict clinical outcome for patients with cancer and could be a new tool for designing vaccines and immunotherapies.

Thursday 25th January 2018

No Benefit With Bevacizumab Maintenance Therapy for Metastatic CRC During Chemo-Free Intervals

Adding bevacizumab maintenance therapy failed to improve outcomes compared with no treatment when administered during chemotherapy-free intervals to patients with metastatic colorectal cancer after induction chemotherapy.

Wednesday 24th January 2018

ASCO Guideline Offers Recommendations for Management of Mesothelioma

ASCO recently released a clinical practice guideline on the treatment of malignant pleural mesothelioma, including recommendations on diagnosis, staging, and treatment with chemotherapy, surgical cytoreduction, and radiation therapy.

Tuesday 23rd January 2018

Engineered Tumor-Specific T Cells May Help Relapsed Hodgkin Lymphoma Patients

A recent study found that Hodgkin lymphoma patients with active disease achieved clinical responses with tumor-specific T cells that were genetically modified to be rendered resistant to transforming growth factor beta, a cytokine expressed by most human cancers.

Engineered Tumor-Specific T-Cells May Help Relapsed Hodgkin Lymphoma Patients

A recent study found that Hodgkin lymphoma patients with active disease achieved clinical responses with tumor-specific T-cells that were genetically modified to be rendered resistant to transforming growth factor beta, a cytokine expressed by most human cancers.

Nivolumab Plus Ipilimumab Offers Improved Survival Outcomes in Certain Metastatic CRC Patients

Patients with DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer who received nivolumab along with ipilimumab had high response rates and improved survival outcomes compared with those who received nivolumab alone.

Monday 22nd January 2018

Metastatic Melanoma Patients May Benefit from Beta Blockers

Researchers discovered that melanoma patients who received immunotherapy while taking a pan beta blocker lived longer than patients who received immunotherapy alone.

Quick Search


News Quicklinks